Pyoderma Gangrenosum Clinical Trial
Official title:
A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum
This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.
At the start of the study (week 0), all patients will receive one subcutaneous injection of
150mg Canakinumab. Patients are then going to be examined at weeks 2, 4, 8, 12 and 16.
At 2 weeks, all patients are going to be evaluated for response by Physician's global
assessment (PGA) of the target lesion. Patients with PGA 0-1 are not going to receive
another injection at this timepoint, while patients with PGA 2-4 are going to receive
another 150mg Canakinumab.
At 4 weeks, in case of PGA 4, patients are going to be offered a first or second line drug
as an alternative therapy (corticosteroids, cyclosporin A or infliximab, dosage see below
"Alternative therapy in case of missing response") and stay within the trial (due to the
long half-life of canakinumab) until week 8.
At week 8, patients with PGA 0 receive another 150mg Canakinumab only, and patients with PGA
4 are not going to receive additional study drug, but are strongly encouraged to attend
following medical visits for observation until the end of the study and/or switch to a first
or second line drug as alternative therapy (see below). All other patients with PGA 1-3
receive the total accumulative dose of Canakinumab that they had received on week 0 and 2,
namely 150 or 300mg.
The study duration for each individual is going to be 16 weeks. At week 8 and 16, safety
laboratory investigations with blood differential (Neutrophil granulocytes, monocytes,
eosinophils, basophils, lymphocytes, thrombocytes, erythrocytes, hemoglobin), AST, ALT,
y-GT, AP, Bilirubin (total), Creatinine, Na, K, CRP are going to be determined.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06092216 -
Spesolimab in Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT03311464 -
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
|
Phase 3 | |
Recruiting |
NCT04901325 -
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
|
Phase 2 | |
Completed |
NCT00791557 -
Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
|
N/A | |
Terminated |
NCT02318914 -
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
|
Phase 3 | |
Terminated |
NCT02315417 -
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
|
Phase 3 | |
Completed |
NCT03137160 -
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Not yet recruiting |
NCT05984654 -
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
|
N/A | |
Completed |
NCT04895566 -
Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
|
Early Phase 1 | |
Withdrawn |
NCT04274166 -
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT01882504 -
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Withdrawn |
NCT00730717 -
Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT03971643 -
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
|
Phase 2 | |
Not yet recruiting |
NCT04792957 -
JAK-STAT Signaling Pathway in Pyoderma Gangrenosum
|
||
Not yet recruiting |
NCT05821374 -
Deucravacitinib in PG
|
Early Phase 1 | |
Terminated |
NCT03072953 -
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
|
Phase 2 | |
Recruiting |
NCT05120726 -
A Novel Therapeutic Treatment of Pyoderma Gangrenosum
|
Phase 4 | |
Withdrawn |
NCT00690846 -
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
|
Phase 2 | |
Completed |
NCT01965613 -
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
|
Phase 2 | |
Recruiting |
NCT01952275 -
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
|
N/A |